Point-of-care testing in an organ procurement organization donor management setting.

Organ procurement organizations rely on timely and accurate diagnostic data to optimize donor management. Prior research has shown that delays in test results can affect clinical decisions regarding organ viability. However, no prior work had resolved how point-of-care testing might influence both clinical outcomes and financial efficiency in this setting. While established knowledge supports the use of centralized laboratory testing, uncertainty remained about whether portable testing could match its accuracy. This gap motivated an evaluation of whether a portable device could provide comparable results while reducing wait times. No prior work had resolved the financial implications of replacing hospital lab testing with a point-of-care system. That uncertainty drove the need to assess both clinical and economic impacts. This study aimed to bridge the gap between traditional lab testing and the potential benefits of rapid on-site diagnostics. The research focused on whether a specific device could meet these dual criteria of accuracy and cost-effectiveness.

The study aimed to evaluate the clinical and financial impacts of using a portable blood analyzer in the management of deceased organ donors. The specific problem addressed was the need for faster, more accessible diagnostic results to improve donor care and reduce costs. The motivation stemmed from the limitations of relying on hospital laboratory turnaround times, which can delay critical interventions. No prior work had resolved whether a portable device could provide equivalent data to traditional labs. That uncertainty drove the need to compare the device's results with those from hospital labs. The study also sought to quantify the financial savings associated with using the device. This dual focus on accuracy and cost was essential to determine the device's viability in routine donor management. The research sought to provide evidence-based support for integrating point-of-care testing into standard OPO protocols.

The research team conducted a comparative analysis of test results from a portable device and hospital lab results for 15 donors. They selected specific analytes such as pH, PCO2, and electrolytes for comparison. The study spanned from March to May 2001 to capture a representative sample. They used correlation coefficients to assess the agreement between the two testing methods. The financial impact was evaluated by analyzing data from 77 donors over a nine-month period. Billing records were reviewed to calculate the cost savings associated with the device. The team focused on whether the device could match the accuracy of hospital labs. They also measured how quickly the device provided results compared to traditional methods. The study design allowed for both qualitative and quantitative assessments of the device's performance.

The study found strong correlations between the portable device and hospital lab results for all tested analytes. The correlation coefficients ranged from 0.86 for hematocrit to 0.98 for PO2 and sodium. These values suggest a high level of agreement between the two testing methods. The device provided results with a quicker turnaround time than the hospital lab. This faster availability allowed for more immediate clinical decisions regarding donor management. The study also reported an average financial saving of US$733 per case. These savings were attributed to the elimination of billing for the device's tests. The results indicate that the device can replace hospital lab testing without compromising accuracy. The financial and clinical benefits were consistent across the study period.

The authors concluded that the portable device provides results equivalent to those of hospital labs. The strong correlations support the device's accuracy in measuring key analytes. The quicker turnaround time allows for faster clinical decisions in donor management. The financial savings of US$733 per case were a direct result of not billing for the device's tests. The study supports the use of the device in routine donor management protocols. The authors suggest that this approach can improve both the efficiency and cost-effectiveness of donor care. The findings indicate that the device is a viable alternative to traditional lab testing. The authors propose that this method could be adopted in other organ procurement organizations.